SCHEMBL3014287

SCHEMBL3014287

O=S(=O)(c1cccc(Br)c1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CTSS P25774 1/20 0.33
HTR2A P28223 4/20 0.32
PROKR1 Q8TCW9 3/20 0.32
FPR2 P25090 2/20 0.32
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32
MBTD1 Q05BQ5 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
GPR6 P46095 1/20 0.32
DRD4 P21917 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
HTR2C P28335 3/20 0.31
KCNH2 Q12809 3/20 0.31
DRD2 P14416 2/20 0.31
DNM1L O00429 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003569 0.93 SOS1 (0.35) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3021350 0.92 RAB9A (0.34) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3016075 0.92 L3MBTL1 (0.35) RAB9ANPC1SMN1; SMN2HTR2AMBTD1
SCHEMBL3015341 0.91 GPR6 (0.39) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3013571 0.91 RAB9A (0.38) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3010530 0.91 HTR2A (0.35) RAB9ANPC1SMN1; SMN2HTR2APROKR1
SCHEMBL3003523 0.89 HTR2A (0.38) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3001961 0.89 HTR2A (0.34) RAB9ANPC1SMN1; SMN2CTSSHTR2A
SCHEMBL3008542 0.89 MAPT (0.36) RAB9ANPC1SMN1; SMN2HTR2AMBTD1
SCHEMBL3014833 0.89 L3MBTL1 (0.35) RAB9ANPC1SMN1; SMN2HTR2APROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.